Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised, Double-blind, parallel-group, active-comparator(venlafaxine extended release), fixed-dose study of LuAA21004 in Major Depressive Disorder in Asian countries

Next Previous
Trial Profile

Randomised, Double-blind, parallel-group, active-comparator(venlafaxine extended release), fixed-dose study of LuAA21004 in Major Depressive Disorder in Asian countries

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Mar 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vortioxetine (Primary) ; Venlafaxine
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Acronyms SOLUTION
  • Sponsors Lundbeck A/S

Most Recent Events

  • 06 Nov 2019 Results assessing treatment success of vortioxetine versus venlafaxine XR and cost-Effectiveness were presented at the 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
  • 24 Sep 2019 Results (n=186) of pooled analysis of this and other two studies (NCT01676571 and NCT02386488) assessing pharmacokinetic analysis in Chinese and non-Chinese healthy subjects, published in the Advances in Therapy.
  • 24 May 2017 Results assessing the overall performance priority the antidepressants: vortioxetine, agomelatine and venlafaxine XR in patients from two randomised trials (SOLUTION and REVIVE), presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top